SOURCE: ClearTrial, LLC

August 02, 2005 11:30 ET

MAP Pharmaceuticals Selects ClearTrial to Expedite Clinical Trial Planning and Outsourcing

OAKBROOK TERRACE, IL -- (MARKET WIRE) -- August 2, 2005 -- ClearTrial, LLC, a leading provider of Clinical Trial Operations (CTO) software, today announced that MAP Pharmaceuticals has selected the ClearTrial Planner™ software to plan, forecast and budget their clinical trials and to help optimize their operational execution of those trials.

"ClearTrial's software artfully abstracts the complex process of planning clinical studies into an elegant, fast and simple-to-use system," said Dr. Stephen Shrewsbury, Vice President, Clinical and Regulatory Affairs at MAP Pharmaceuticals, Inc. "Our rapidly evolving, cost-constrained industry will benefit from this integratable solution that ClearTrial provides."

MAP Pharmaceuticals, Inc. will use the ClearTrial™ Planner in the planning and outsourcing of two forthcoming studies. The first is for MAP's lead product candidate, unit dose budesonide (UDB), which is a novel nebulized form of budesonide, a steroid currently used to treat pediatric asthma. The product is being developed as a first-line therapy for the treatment of acute and chronic pediatric asthma. MAP will also use ClearTrial's software for upcoming studies for its proprietary Tempo™ Inhaler platform. Tempo™ is a next-generation pressurized metered-dose inhaler (pMDI) that is designed for the pulmonary delivery of respiratory and systemic drug therapies.

"MAP's ability to innovate doesn't stop with the novel therapies and inhalation delivery technologies that they are developing," said Michael Soenen, Chief Operating Officer at ClearTrial. "Their selection of the ClearTrial software shows that they apply that same innovative thinking to their business operations."

About ClearTrial

ClearTrial (www.cleartrial.com) is a leading provider of Clinical Trial Operations software. ClearTrial's software helps pharmaceutical, biotechnology, medical device companies and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information, please visit www.cleartrial.com.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals, Inc. is a specialty pharmaceutical company developing innovative therapies and inhalation delivery platforms to treat a broad spectrum of respiratory and systemic diseases. MAP's lead product is a proprietary formulation of budesonide for the treatment of pediatric asthma. The Company is also developing a series of respiratory and inhaled systemic drugs based on its Tempo™ Inhaler platform, including a rapid-relief treatment for migraine. Tempo™ is a next-generation breath-actuated pMDI that automatically adjusts to different inhalation maneuvers but is exceptionally easy to use, enhancing compliance. Tempo™ also features a novel aerosol flow controller that ensures efficient and consistent delivery of the drug to the lungs, while minimizing oral deposition. For more information, please visit www.mappharma.com.

ClearTrial™, ClearTrial Planner™, and the ClearTrial logo are trademarks and/or service marks owned by ClearTrial, LLC, which may be registered in certain jurisdictions.

Contact Information

  • Press Contact:
    Karen Rancic
    ClearTrial
    312.933.3409